Keywords: Forest Labs, Pierre Fabre, Levomilnacipran, Ph III, Major despressive disorder

Forest Labs and Pierre Fabre's levomilnacipran positive in Ph III

Article | 07 March 2012

Print This

US drugmaker Forest Laboratories (NYSE: FRX) and France-based Pierre Fabre have announced positive top-line results in a Phase III clinical ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in